报价延迟最少15分钟:2026/03/02 12:20 EST
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
33.31 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-1.72/0.47
|
|
企业价值
4.02B
|
| 资产负债 |
|
每股账面净值
5.94
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
22.50M
|
|
每股收益
0.13
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比较之报价最少15分钟延迟 (夜盘时段除外)
|
业务概览
|
|||
| NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments. The Company has one reportable segment, which comprises the discovery, development, and commercialization of transformative therapies for cardio-metabolic diseases. |
